| Literature DB >> 34499866 |
Kerri A Johannson1, Nazia Chaudhuri2, Ayodeji Adegunsoye3, Paul J Wolters4.
Abstract
Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.Entities:
Mesh:
Year: 2021 PMID: 34499866 DOI: 10.1016/S0140-6736(21)01826-2
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321